Analysts expect Fair Isaac Corporation (NYSE:FICO) to report $1.03 EPS on April, 25.They anticipate $0.05 EPS change or 4.63% from last quarter’s $1.08 EPS. FICO’s profit would be $29.94 million giving it 63.92 P/E if the $1.03 EPS is correct. After having $0.88 EPS previously, Fair Isaac Corporation’s analysts see 17.05% EPS growth. The stock decreased 2.13% or $5.74 during the last trading session, reaching $263.33. About 170,830 shares traded. Fair Isaac Corporation (NYSE:FICO) has risen 46.26% since March 24, 2018 and is uptrending. It has outperformed by 41.89% the S&P500. Some Historical FICO News: 26/04/2018 – Fair Isaac Raises 2018 View To Rev $1.02B; 18/04/2018 – FICO Solution for ldentifying Procurement Fraud, Waste and Abuse Now on Amazon Web Services (AWS); 02/04/2018 – Fair Isaac Corp.: Resignation Result of Begor’s Appointment as CEO of Equifax Inc; 18/04/2018 – FICO Amplifies Financial Crime Protection with New Suite of Solutions; 11/04/2018 – FICO Welcomes Amazon Web Services (AWS) to FICO World as Platinum Sponsor; 06/03/2018 – AI Innovator Sebastian Thrun and Chess Grandmaster Garry Kasparov to Headline FICO World 2018; 27/04/2018 – FICO Delivers Mission Critical Artificial Intelligence in the Cloud; 30/04/2018 – S&PGR Rates Fair Isaac Corp. ‘BB+’, Outlook Stable; Debt Rated; 26/04/2018 – Fair Isaac Raises 2018 View To Adj EPS $6.38; 11/04/2018 – FICO Survey: 70% of APAC Banks Will Use Al in Collections and Recovery by 2019
Trexquant Investment Lp decreased Array Biopharma Inc (ARRY) stake by 46.35% reported in 2018Q4 SEC filing. Trexquant Investment Lp sold 56,678 shares as Array Biopharma Inc (ARRY)’s stock rose 45.15%. The Trexquant Investment Lp holds 65,609 shares with $935,000 value, down from 122,287 last quarter. Array Biopharma Inc now has $4.91B valuation. The stock decreased 6.25% or $1.5 during the last trading session, reaching $22.49. About 3.06M shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 33.98% since March 24, 2018 and is uptrending. It has outperformed by 29.61% the S&P500. Some Historical ARRY News: 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 09/04/2018 – Merck: Keytruda Monotherapy Meets Primary Endpoint in Phase 3 Study; 25/04/2018 – EC OKS BRISTOL-MYERS SQUIBB’S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSI; 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2; 08/03/2018 – Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 18/04/2018 – U.S. FDA Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Small Cell Lung Cancer and Grants Priority Review; 08/05/2018 – NEON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN CLINICAL TRIAL EVALUATING PERSONAL CANCER VACCINE NEO-PV-01 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AND CHEMOTHERAPY; 09/04/2018 – KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor; 06/04/2018 – INCYTE- SAFETY PROFILE OBSERVED IN ECHO-301/KEYNOTE-252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA; 09/04/2018 – Merck’s Keytruda meets main goal in lung cancer trial
Investors sentiment increased to 0.88 in 2018 Q4. Its up 0.03, from 0.85 in 2018Q3. It is positive, as 37 investors sold Fair Isaac Corporation shares while 97 reduced holdings. 46 funds opened positions while 72 raised stakes. 23.69 million shares or 7.31% more from 22.08 million shares in 2018Q3 were reported. Guggenheim Capital Lc reported 6,688 shares. Ameritas Inv Partners holds 0.09% or 8,510 shares in its portfolio. Virginia Retirement Et Al stated it has 8,000 shares or 0.02% of all its holdings. 34,869 are owned by Bnp Paribas Arbitrage. Rafferty Asset Mngmt Ltd Llc owns 4,981 shares. Delta Asset Management Ltd Liability Tn holds 50 shares or 0% of its portfolio. Tci Wealth Advsr Inc holds 0% or 27 shares in its portfolio. Marshall Wace Llp has invested 0.01% in Fair Isaac Corporation (NYSE:FICO). Neuberger Berman Grp Incorporated Lc holds 0.29% or 1.11 million shares. Rmb Capital Management Limited Liability stated it has 0.21% in Fair Isaac Corporation (NYSE:FICO). Invesco stated it has 606,349 shares. Cibc World Mkts Corp holds 55,700 shares or 0.1% of its portfolio. San Francisco Sentry Invest (Ca) accumulated 12 shares. State Of Alaska Department Of Revenue has invested 0.01% in Fair Isaac Corporation (NYSE:FICO). Trexquant Inv L P holds 0.08% or 7,164 shares in its portfolio.
Fair Isaac Corporation develops analytic, software, and data management services and products that enable businesses to automate, enhance, and connect decisions. The company has market cap of $7.66 billion. The firm offers analytical solutions, credit scoring, and credit account management services and products to banks, credit reporting agencies, credit card processing agencies, insurers, retailers, healthcare organizations, and public agencies. It has a 54.31 P/E ratio. It operates through three divisions: Applications, Scores, and Decision Management Software.
Since October 9, 2018, it had 0 buys, and 17 sales for $29.59 million activity. $1.79M worth of Fair Isaac Corporation (NYSE:FICO) was sold by Wells Stuart. Shares for $2.17 million were sold by Wehmann James M. Leonard Michael S sold $470,767 worth of stock or 2,000 shares. $2.32 million worth of Fair Isaac Corporation (NYSE:FICO) was sold by Scadina Mark R on Wednesday, February 6. The insider Huyard Wayne Elliot sold 5,000 shares worth $1.18M.
More notable recent Fair Isaac Corporation (NYSE:FICO) news were published by: Prnewswire.com which released: “US Senator Catherine Cortez Masto and Congressman Steven Horsford Joins FICO at Free Consumer Financial Education Event in Las Vegas – PRNewswire” on March 11, 2019, also Prnewswire.com with their article: “FICO Survey: Auto Dealership Financing Holds Strong Among Consumers while Online Loans Gain Traction – PRNewswire” published on March 13, 2019, Seekingalpha.com published: “FICO plans big change to credit scores – Seeking Alpha” on October 23, 2018. More interesting news about Fair Isaac Corporation (NYSE:FICO) were released by: Seekingalpha.com and their article: “More on Fair Isaac Q1 results – Seeking Alpha” published on January 31, 2019 as well as Seekingalpha.com‘s news article titled: “Fair Isaac Corp. (FICO) CEO Will Lansing on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 03, 2018.
Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on May, 8. They expect $-0.20 earnings per share, down 81.82% or $0.09 from last year’s $-0.11 per share. After $-0.05 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 300.00% negative EPS growth.
Trexquant Investment Lp increased Blackberry Ltd (NASDAQ:BBRY) stake by 214,187 shares to 278,728 valued at $1.98M in 2018Q4. It also upped Tapestry Inc stake by 87,034 shares and now owns 149,280 shares. Lennar Corp (NYSE:LEN) was raised too.
Among 5 analysts covering Array BioPharma (NASDAQ:ARRY), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Array BioPharma had 7 analyst reports since December 13, 2018 according to SRatingsIntel. J.P. Morgan maintained the stock with “Buy” rating in Thursday, March 14 report. Cantor Fitzgerald maintained the shares of ARRY in report on Monday, March 11 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, March 18 report. The stock has “Buy” rating by Cowen & Co on Wednesday, March 13.
More notable recent Array BioPharma Inc. (NASDAQ:ARRY) news were published by: Prnewswire.com which released: “Array BioPharma to Present at the 39th Annual Cowen Health Care Conference – PRNewswire” on March 05, 2019, also Benzinga.com with their article: “Daily Biotech Pulse: KaryoPharm’s Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA – Benzinga” published on March 15, 2019, Gurufocus.com published: “Weekly Top Insider Buys Highlight for the Week of Feb. 22 – GuruFocus.com” on February 23, 2019. More interesting news about Array BioPharma Inc. (NASDAQ:ARRY) were released by: Globenewswire.com and their article: “Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences â€” Renewed Outlook, Key Drivers of Growth – GlobeNewswire” published on March 04, 2019 as well as Nasdaq.com‘s news article titled: “Has Array BioPharma (ARRY) Outpaced Other Medical Stocks This Year? – Nasdaq” with publication date: January 29, 2019.